Market Overview

Why PPD's Stock Is Trading Higher Today


PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.

PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services.

The company was taken private in 2011 and went public again in 2020.

PPD shares were trading up 5.3% at $27.90 at time of publication. The stock has a 52-week high of $33.23 and a 52-week low of $10.61.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually

Latest Ratings for PPD

Oct 2020Deutsche BankMaintainsBuy
Oct 2020Truist SecuritiesInitiates Coverage OnBuy
Sep 2020KeyBancMaintainsOverweight

View More Analyst Ratings for PPD
View the Latest Analyst Ratings


Related Articles (PPD)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Price Target Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at